| Name | Interleukin-12 subunit beta | ||
| UniProt ID | IL12B_HUMAN | ||
| Gene Name | IL12B | ||
| Gene ID | 3593 | ||
| Synonyms |
IL12B, CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2
|
||
| Sequence |
MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITW
TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKN LQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVIC RKNASISVRAQDRYYSSSWSEWASVPCS |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa3593 | ||
| TTD ID | T95385 | ||
| Pfam | PF00041; PF00047; PF10420; PF13895; PF13927; PF16680; PF16681 | ||
| Pair Name | Vitamin C, Anti-PD-1 antibody | |||
| Phytochemical | Vitamin C | |||
| Drug | Anti-PD-1 antibody | |||
| Disease Info | [ICD-11: 2B33.5] | Lymphoma | Investigative | |
| Regulate Info | Up-regulation | Interleukin-12 subunit beta | Expression | |
| Result | This study shows that AA treatment 1) increases immunogenicity of lymphoma cells; 2) enhances intratumoral infiltration of CD8+ T cells and macrophages; and 3) synergizes with anti-PD1 checkpoint inhibition in a syngeneic lymphoma mouse model via marked activation of cytotoxic cells (cytotoxic T cells and NK cells) and antigen presenting cells. The data provide a compelling rationale for testing combinations of high-dose AA and anti-PD1 agents in patients with aggressive B cell lymphoma and in preclinical models of other malignancies. | |||
